Back to Stakeholders
Categories

2 domains / 4 areas / 3 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Psychedelic Healthcare ImplementationHealth EconomistsPayer & Reimbursement Stakeholders
Government, Policy & Advocacy
Government, Policy & Advocacy
Public Sector Health & Drug GovernanceHealth Technology Assessment Agencies

Federal Joint Committee (G-BA)

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

Public Payer / National Coverage Authority

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessLong-Term SafetyPatient-Reported OutcomesReal-World Evidence

Market Access Notes

G-BA publishes formal benefit-assessment resolutions that directly shape German reimbursement access; esketamine has an AMNOG evaluation and English resolution materials.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Source Evidence

G-BA - Benefit Assessment Procedure (Esketamine)

https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/931/

G-BA - Resolution (English PDF) Esketamine

https://www.g-ba.de/downloads/39-1464-6170/2023_09_21_AM-RL-XII_Esketamin_D-930_EN.pdf

Quick Facts

Website
Visit